Premenstrual Dysphoric Disorder
Conditions
Interventions
This is a randomized two-armed, double-blind trial. Experimental group: 30 adult women with premenstrual dysphoric disorder, who will undergo the five sessions of repetitive transcranial magnetic stim
E02.621.820
Sponsors
Universidade Federal de Pernambuco
Universidade Federal de Pernambuco
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Confirmed diagnosis of premenstrual dysphoric disorder; Age 18 years or older; Regular menstrual cycles, lasting between 21-35 days; Availability to attend the service on the days designated for the intervention. .
Exclusion criteria
Exclusion criteria: Lifelong diagnosis of depression, bipolar disorder or schizophrenia (confirmed by a psychiatrist); Use of psychotropic drugs ("controlled drugs"), in the last 04 weeks; Risk of committing suicide; Pregnancy; Absolute contraindication to transcranial magnetic stimulation, such as having cochlear implant (device to treat deafness) or intracranial metal objects (such as clips for cerebral aneurysm and metal plates); history of seizure in the last 12 months or diagnosis of epilepsy; Treatment with transcranial magnetic stimulation, electroconvulsive therapy or transcranial direct current stimulation in the last 12 months; Alcohol or other drug abuse in the last 06 months; Use of any continuous oral contraceptive ("which make the woman do not have menstruation") or containing the substance drospireone ; subcutaneous hormonal implant ("implanon"); or injectable contraceptives; or intrauterine hormonal device ("Mirena IUD");
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study is to achieve a significantly greater reduction in premenstrual symptoms in patients in the experimental group, measured by the score in the "Screening Tool for Premenstrual Symptoms" for 2 consecutive menstrual cycles. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to find a more significant reduction in the score obtained in the premenstrual symptoms, recorded in the "Daily Registry of Intensity of Problems", in the experimental group, as well as a greater decrease in scores related to depressive and anxious symptoms, and similar rates of adverse effects in both groups. It is also expected to identify possible predictors of favorable response to treatment. | — |
Countries
Brazil
Contacts
Public ContactDennison Monteiro
Instituto Monteiro de Neuromodulação
Outcome results
None listed